Nolan Sean P. — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Nolan Sean P. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $840K.

Profile

Nolan Sean P.

Sean P. Nolan is the Chief Executive Officer of Taysha Gene Therapies, Inc. (TSHA) as of the most recent SEC filing dated 2026-01-14. TSHA is a patient-centric gene therapy company focused on developing AAV-based treatments for monogenic CNS diseases, including the TSHA-102 program.

RoleDirector
Notability45/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-05-15VTRVentas, Inc.A — Grant or award2.0K$90.35$185K
2026-01-27TSHATaysha Gene Therapies, Inc.S — Open-market sale41.3K$4.61$190K
2026-01-27TSHATaysha Gene Therapies, Inc.S — Open-market sale136.8K$4.75$650K
2026-01-14TSHATaysha Gene Therapies, Inc.A — Grant or award1.01M$0.00

Companies — Last 90 Days

Frequently Asked Questions

Who is Nolan Sean P.?

Sean P. Nolan is the Chief Executive Officer of Taysha Gene Therapies, Inc. (TSHA) as of the most recent SEC filing dated 2026-01-14. TSHA is a patient-centric gene therapy company focused on developing AAV-based treatments for monogenic CNS diseases, including the TSHA-102 program.…

How many SEC Form 4 filings has Nolan Sean P. submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has Nolan Sean P. been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 2 open-market sales ($840K) across all tracked filings.

Where can I see all of Nolan Sean P.'s SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Nolan Sean P. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.